Syapse is the developer of a platform that works with leading health systems, life sciences companies, and regulators to accelerate real-world evidence to improve the outcomes of cancer patients.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
02/02/2021 | Series G-2 | $30.15MM | $xx.xx | $19.29B | Ally Bridge Group, Northpond Ventures | |
Price per Share
$xx.xx
Shares Outstanding
60,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Northpond Ventures
|
||||||
02/02/2021 | Series G-1 | $41.21MM | $xx.xx | $19.29B | Ally Bridge Group, Northpond Ventures | |
Price per Share
$xx.xx
Shares Outstanding
82,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ally Bridge Group, Northpond Ventures
|
||||||
05/28/2020 | Series F | $39.26MM | $xx.xx | $11.26B | Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Revelation Alpine, Roche Finance, Safeguard Scientifics, Social Capital | |
Price per Share
$xx.xx
Shares Outstanding
85,047,159
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, Ascension Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, Revelation Alpine, Roche Finance, Safeguard Scientifics, Social Capital
|
||||||
04/23/2019 | Series E | $24.1MM | $xx.xx | $23.98B | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
13,256,324
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.3x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
11/14/2017 | Series D | $27MM | $xx.xx | $13.04B | Amgen Ventures, Ascension Ventures, Ge Ventures, Intermountain Healthcare Innovation Fund, Medidata Solutions, Merck Global Health Innovation Fund, Roche Venture Fund, Safeguard Scientifics, Social Capital | |
Price per Share
$xx.xx
Shares Outstanding
25,006,941
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amgen Ventures, Ascension Ventures, Ge Ventures, Intermountain Healthcare Innovation Fund, Medidata Solutions, Merck Global Health Innovation Fund, Roche Venture Fund, Safeguard Scientifics, Social Capital
|
||||||
01/12/2016 | Series C | $26.5MM | $xx.xx | $8.83B | Ascension Ventures, Safeguard Scientifics, Social Capital | |
Price per Share
$xx.xx
Shares Outstanding
25,916,868
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.2x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Ascension Ventures, Safeguard Scientifics, Social Capital
|
||||||
07/10/2014 | Series B | $9.75MM | $xx.xx | $3.08B | Safeguard Scientifics, Social Capital | |
Price per Share
$xx.xx
Shares Outstanding
13,636,363
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Safeguard Scientifics, Social Capital
|
||||||
01/01/2013 | Series A | $3.8MM | $xx.xx | $843.43MM | Social Capital | |
Price per Share
$xx.xx
Shares Outstanding
7,923,661
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Social Capital
|